Clinical trial
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
NCT00115739 · University of Michigan Rogel Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00115739 |
|---|---|
| Title | Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma |
| Official title | Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Cancer |
| Intervention type | Drug |
| Interventions | Imatinib |
| Enrollment | 11 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | Aug 1, 2010 |
| First posted | Jun 24, 2005 |
| Last update posted | Apr 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: